The evidence reviewed above indicates that the GRPR might be considered a novel molecular target in different types of CNS disorders, and raise the possibility that GRPR agonists might ameliorate cognitive and social deficits associated with neurological diseases, while antagonists may, for example, reduce anxiety and inhibit the growth of some types of brain cancer. This evidence concerns the gene GRPR and Anxiety.